Finanzen von Kyntra Bio Inc (KYNB)KYNBKyntra Bio Inc

Evaluating the bottom line, Kyntra Bio, Inc. maintains a gross margin of -81.45%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -1385.11%, while the net margin is -139.49%. These profitability ratios, combined with a Return on Equity (ROE) of N/A, provide a clear picture of how effectively KYNB converts its operational activities into shareholder value.

In the context of the broader market, KYNB competes directly with industry leaders such as COCP and CNTX. With a market capitalization of $15.33M, it holds a significant position in the sector. When comparing efficiency, KYNB's gross margin of -81.45% stands against COCP's 100.00% and CNTX's N/A. Such benchmarking helps identify whether Kyntra Bio, Inc. is trading at a premium or discount relative to its financial performance.

Kyntra Bio has shown mixed financial performance with a recent net income of $12 million in Q2 2026, but it has also faced significant losses in previous quarters, including a net loss of $15.2 million in Q1 2026 and a gross margin of -81.45% in Q2 2026, indicating ongoing financial struggles.